Novametrix pulse oximeter cleared by FDA:
This article was originally published in Clinica
Novametrix Medical Systems has received US FDA clearance for its MARSpo2 Tech pulse oximeter. The device provides accurate oxygen and pulse rate information as well as enhancing pulse oximetry performance on patients who experience significant motion or who endure poor blood flow. The pulse oximeter alleviates problems associated with more traditional oximeters, including high operating costs and poor performance, the Wallingford, Connecticut-based company said.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.